Ototoxicity and Teprotumumab

Ann Otol Rhinol Laryngol. 2022 Aug;131(8):910-913. doi: 10.1177/00034894211042740. Epub 2021 Aug 27.


Objectives: Teprotumumab, a novel monoclonal antibody, targets the insulin-like growth factor 1 (IGF-1) receptor. IGF-1 receptors, found in muscle and fat adjacent to the eye and implicated in Graves Ophthalmopathy, are also in the cochlea. In clinical trials, 5 participants reported self-limited audiologic symptoms but there are no objective data in the literature. The aim of this report is to describe one of the first known cases of teprotumumab-induced irreversible sensorineural hearing loss.

Methods: Case report at a tertiary referral center.

Results: A 61 year old female with Graves ophthalmopathy presented with bilateral hearing loss, sound distortion, and tinnitus following treatment with teprotumumab. Audiogram showed mild sloping to moderately-severe sensorineural hearing loss. Repeat audiometry obtained 4 months after cessation of teprotumumab and treatment with oral corticosteroids was unchanged.

Conclusions: This is one of the first descriptive cases of ototoxicity resulting in irreversible sensorineural hearing loss in the setting of treatment with teprotumumab. Periodic audiologic evaluations should be recommended to patients on teprotumumab.

Keywords: audiometry; graves ophthalmopathy; hearing loss; miscellaneous; otolaryngology; otology; ototoxicity; teprotumumab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Female
  • Graves Ophthalmopathy* / drug therapy
  • Hearing Loss, Sensorineural* / chemically induced
  • Hearing Loss, Sensorineural* / diagnosis
  • Hearing Loss, Sensorineural* / drug therapy
  • Humans
  • Middle Aged
  • Ototoxicity*


  • Antibodies, Monoclonal, Humanized
  • teprotumumab